EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks by L. Gouya et al.
1Hepatology, Vol. 0, No. 0, 2019 
EXPLORE: A Prospective, Multinational, 
Natural History Study of Patients with 
Acute Hepatic Porphyria with Recurrent 
Attacks
Laurent Gouya,1-3 Paolo Ventura,4* Manisha Balwani ,5* D. Montgomery Bissell,6 David C. Rees,7 Ulrich Stölzel,8  
John D. Phillips,9 Raili Kauppinen,10 Janneke G. Langendonk,11 Robert J. Desnick,5 Jean-Charles Deybach,1-3  
Herbert L. Bonkovsky ,12 Charles Parker,9 Hetanshi Naik,5 Michael Badminton,13 Penelope E. Stein,7 Elisabeth Minder,14  
Jerzy Windyga,15 Radan Bruha,16 Maria Domenica Cappellini,17 Eliane Sardh,18 Pauline Harper,18 Sverre Sandberg,19  
Aasne K. Aarsand,19 Janice Andersen,19 Félix Alegre,20 Aneta Ivanova,21 Neila Talbi,1-3 Amy Chan,22 William Querbes,22 John Ko,22 
Craig Penz,22 Shangbin Liu,22 Tim Lin,22 Amy Simon,22 and Karl E. Anderson23
BaCKgRoUND aND aIMS: Acute hepatic porphyria 
comprises a group of rare genetic diseases caused by muta-
tions in genes involved in heme biosynthesis. Patients can 
experience acute neurovisceral attacks, debilitating chronic 
symptoms, and long-term complications. There is a lack of 
multinational, prospective data characterizing the disease and 
current treatment practices in severely affected patients.
appRoaCH aND ReSUltS: EXPLORE is a prospective, 
multinational, natural history study characterizing disease ac-
tivity and clinical management in patients with acute hepatic 
porphyria who experience recurrent attacks. Eligible patients 
had a confirmed acute hepatic porphyria diagnosis and had 
experienced ≥3 attacks in the prior 12  months or were receiv-
ing prophylactic treatment. A total of 112 patients were en-
rolled and followed for at least 6  months. In the 12  months 
before the study, patients reported a median (range) of 6 
(0-52) acute attacks, with 52 (46%) patients receiving hemin 
prophylaxis. Chronic symptoms were reported by 73 (65%) 
patients, with 52 (46%) patients experiencing these daily. 
During the study, 98 (88%) patients experienced a total of 
483 attacks, 77% of which required treatment at a health 
care facility and/or hemin administration (median [range] an-
nualized attack rate 2.0 [0.0-37.0]). Elevated levels of hepatic 
δ-aminolevulinic acid synthase 1 messenger ribonucleic acid lev-
els, δ-aminolevulinic acid, and porphobilinogen compared with 
the upper limit of normal in healthy individuals were observed 
at baseline and increased further during attacks. Patients had 
impaired quality of life and increased health care utilization.
CoNClUSIoNS: Patients experienced attacks often requir-
ing treatment in a health care facility and/or with hemin, as 
well as chronic symptoms that adversely influenced day-to-day 
functioning. In this patient group, the high disease burden 
and diminished quality of life highlight the need for novel 
therapies. (Hepatology 2019;0:1-13).
Acute hepatic porphyria (AHP) comprises a group of rare metabolic diseases caused by mutations in genes encoding enzymes 
involved in heme biosynthesis.(1,2) The four types 
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of AHP are autosomal dominant acute intermittent 
porphyria (AIP), variegate porphyria (VP), hered-
itary coproporphyria (HCP), and the extremely rare 
autosomal recessive δ-aminolevulinic acid (ALA) 
dehydratase deficient porphyria.(3,4) AIP is the most 
common type, with a prevalence of disease-related 
mutations of approximately 1:1,700, with penetrance 
estimated at approximately 20% in families with AIP 
but only 1% in the general population.(5,6)
Induction of the heme synthesis pathway in the 
liver through the initial and rate-limiting enzyme 
δ-aminolevulinic acid synthase 1 (ALAS1) can be 
precipitated by a variety of triggers. In patients with 
AHP, this induction can result in the accumulation 
of toxic heme intermediates, primarily ALA and 
porphobilinogen (PBG), which are likely responsi-
ble for disease manifestations that include potentially 
life-threatening neurovisceral attacks.(7-9)
During attacks, patients typically present with mul-
tiple signs and symptoms caused by dysfunction across 
the autonomic, central, and peripheral nervous systems. 
They often require hospitalization and pain relief with 
opioids.(7,9) Most symptomatic patients have only a 
few attacks in their lifetimes; however, approximately 
3%-8% of symptomatic patients with AIP experience 
recurrent attacks.(10,11) Patients may also experience 
chronic symptoms between attacks,(12-14) a negative 
impact on their physical and emotional health,(4,12) 
and diminished quality of life (QoL).(15) In addi-
tion, long-term complications related to AHP and 
its treatment can occur, including liver disease (e.g., 
cirrhosis and hepatocellular carcinoma),(16,17) chronic 
kidney disease (CKD; as assessed by estimated glo-
merular filtration rate [eGFR]), and systemic arterial 
hypertension.(9,18-20)
Given the rarity of the disease and the nonspecific 
constellation of signs and symptoms, patients typi-
cally experience substantial delays in diagnosis, with 
one study suggesting a mean time to diagnosis of 
15  years from symptom onset.(13) This is of concern, 
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as patients may experience worsening disease man-
ifestations while undergoing diagnostic testing or 
treatment for an incorrect diagnosis. Attacks that are 
not treated promptly can lead to severe neurologic 
damage, require prolonged periods of recovery, or, in 
some cases, are fatal.(9,21,22)
The only approved treatment for acute attacks 
is hemin (heme arginate in Europe and lyophilized 
hematin in the United States), which is administered 
intravenously and acts by down-regulating hepatic 
ALAS1.(23,24) There are no approved pharmaco-
therapies for attack prevention.(25) Current strate-
gies include trigger avoidance (e.g., porphyrinogenic 
drugs, fasting), early ingestion of carbohydrates, sup-
pression of ovulation, and off-label intravenous hemin 
prophylaxis.(7,26) However, prophylactic hemin may 
induce dependence on exogenous heme, has potential 
acute side effects (e.g., infusion site reactions, nau-
sea, fatigue, and headache), and may result in poten-
tial complications related to chronic administration 
(e.g., iron overload, tachyphylaxis, and venous oblit-
eration).(7,11,18,26) Hormonal interventions to prevent 
ovulation include gonadotropin-releasing hormone 
analogs with or without add-back estrogen and low-
dose oral contraceptives(27-29) but are complex and 
applicable only in select patients. In a small number 
of severely affected patients, liver transplantation has 
resulted in normalization of ALA and PBG and the 
cessation of porphyria attacks.(30) Limitations include 
a shortage of donors, highly invasive operations, life-
long immunosuppression therapy, and high rates of 
hepatic artery thrombosis.(30) Thus, there is a high 
unmet medical need for effective treatments.
Addressing these needs is impaired by a limited 
understanding of the natural history of AHP. Although 
there are a few natural history studies characterizing 
patients with AHP and their management,(13,31,32) 
there have been no multinational, prospective, longi-
tudinal studies that document the burden of disease 
in severely affected patients who experience recur-
rent attacks. The present study, EXPLORE, was 
thus designed to characterize the natural history and 
current clinical management of patients with AHP 
experiencing recurrent attacks. Secondary objectives 
included characterization of levels of urinary and 
serum ALA, PBG, and circulating hepatic ALAS1 
mRNA levels during and between attacks; AHP signs 
and symptoms during and between attacks; medical 
and medication history; familial history; QoL; and 
health care utilization.
Patients and Methods
StUDy DeSIgN aND oVeRSIgHt
EXPLORE is a prospective, multinational, obser-
vational, natural history study in patients with AHP 
experiencing recurrent attacks (defined in this 
study as ≥3 porphyria attacks within 12  months 
before the baseline visit) or on prophylactic treat-
ment to prevent attacks. The study was initiated 
in September 2014, completed in November 2016, 
and conducted at 21 centers (7 in the United 
States and 14 in Europe). The study included 
clinical visits (with physical examination, patient 
questionnaires, blood draws, and laboratory assess-
ments) at baseline, 6  months, and an optional visit 
at 12  months, with telephone follow-up every 
2 months (Supporting Table S1). The study design 
was developed in collaboration with the sponsor, 
principal investigators, and the American Porphyria 
Foundation. All patients provided informed con-
sent in writing. The study was approved by central 
and local institutional review boards or ethics com-
mittees according to the International Conference 
on Harmonization for Good Clinical Practice and 
the World Health Organization Declaration of 
Helsinki. The trial is registered at www.Clini calTr 
ials.gov (NCT02240784).
patIeNtS
Male or female patients aged ≥18 years were eli-
gible if they had a diagnosis of AIP, HCP, or VP 
made by a porphyria specialist. Diagnosis was based 
on a history of clinical manifestations of AHP (such 
as acute attacks of abdominal, back, or limb pain), 
biochemical evidence of an AHP attack (≥1 doc-
umented urine or plasma PBG level >4 times the 
upper reference limit), and presence of a patho-
genic genetic mutation. If no mutation had been 
identified by sequencing of relevant heme biosyn-
thesis genes, patients were eligible if they had an 
AIP, HCP, or VP diagnosis made by a porphyria 
specialist, documented PBG elevation, and either 
decreased hydroxymethylbilane synthase activity in 
erythrocytes or increased fecal coproporphyrins with 
a ratio of coproporphyrin III/coproporphyrin I >4 
with or without elevation of fecal protoporphyrin.
Eligible patients had to be experiencing recurrent 
attacks defined by meeting one of the following: ≥3 
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porphyria attacks within 12 months before the base-
line visit, monthly (or more frequent) prophylactic 
hemin treatment (regardless of attack frequency), or 
prophylactic gonadotropin-releasing hormone ana-
log treatment (regardless of attack frequency). At 
least one of the prior attacks had to require hemin 
or treatment at a hospital or in a health care set-
ting (e.g., clinic or infusion center). Patients were 
excluded if they were actively participating in a 
clinical trial of an investigational product. Patients 
could also be excluded if they were not considered 
a good candidate for participation as judged by a 
study investigator.
StUDy aSSeSSMeNtS
Full details of study assessments are in Supporting 
Table S1. In brief, at clinic visits (baseline, Month 6, 
and optional Month 12), patients completed ques-
tionnaires detailing AHP symptoms and treatment, 
QoL (using EuroQoL 5-dimensions questionnaire 
5-levels [EQ-5D-5L], a QoL measure used in 
multiple diseases and population groups(33)), and 
health status. Physical examinations and laboratory 
assessments (including urinary porphyrin precursor 
analysis, liver function tests, hematology, and serum 
chemistry) were also performed, with all samples 
being shipped on dry ice (for sample collection at 
sites) or freezer packs (for home sample collec-
tion) to a central laboratory for analysis. Spot urine 
ALA and PBG were assessed by a validated assay 
at a central laboratory (Covance Laboratory, Utah) 
using liquid chromatography-tandem mass spec-
trometry (LC-MS/MS)(34) and results normalized 
to urine creatinine. The upper reference limit for 
urinary ALA and PBG was established by assessing 
urinary ALA and PBG levels in 150 normal healthy 
subjects.(35) Circulating hepatic ALAS1 mRNA lev-
els (hereafter called ALAS1 mRNA) were mea-
sured in exosomes isolated from spot urine samples 
using the circulating extracellular RNA detection 
assay (as described(36)). ALAS1 mRNA levels are 
expressed relative to normal healthy levels.(36) For 
remote assessments, performed at Months 2 and 4 
and optional Months 8 and 10, patients completed 
questionnaires detailing AHP symptoms and treat-
ment and mailed a spot urine sample to assess PBG 
and ALA levels. Any adverse medical occurrence 
in a patient that was judged by the investigator as 
not related to a study procedure was recorded as a 
change in health status.
DeFINItIoN aND aSSeSSMeNt 
oF aHp attaCKS
An AHP attack was reported by the patient if 
the attack required increased pain medication or 
carbohydrate intake, hemin administration, and/
or hospitalization for signs and symptoms of AHP, 
including but not limited to severe abdominal pain, 
vomiting, tachycardia, constipation, arterial hyper-
tension, or hyponatremia. An attack was defined as 
new if it started at least 1 calendar day after the 
last attack ended. Attacks were classified according 
to the duration and location of attack treatment 
(e.g., home or health care facility). The frequency of 
AHP attacks was assessed by calculating the mean 
annualized attack rate (AAR).
During an attack, urine ALA and PBG levels were 
measured daily, and, to capture symptoms experienced, 
patients completed an attack symptom inventory form 
daily. If the attack required hospitalization, then phys-
ical and neurologic examinations, vital signs, available 
laboratory assessments, and attack treatment were 
recorded. One and 2  weeks after an attack, ongoing 
AHP symptoms were captured during phone inter-
views conducted by study center staff.
StatIStICal aNalySIS
Data from all patients who completed screening 
were analyzed. As EXPLORE is an observational 
study, no formal hypothesis testing was conducted, 
and sample size was not based on statistical con-
siderations. Results were analyzed using descriptive 
statistics.
Results
StUDy popUlatIoN
A total of 112 patients were enrolled, 104 
of whom had AIP, 3 had HCP, and 5 had VP 
(Table 1). Patients were predominantly female 
(89%) and Caucasian (85%), with 56% from Europe 
and 44% from the United States. Ninety-six (86%) 
patients had genotype results available, which identi-
fied 64 distinct mutations in the hydroxymethylbilane 
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synthase gene in patients with AIP. The most com-
mon genotypes were p. R173W (4 [4%] patients) 
and p. W283X (4 [4%] patients). The 8 patients with 
VP and HCP all had distinct genotypes. Six-month 
and optional 12-month follow-up visits were com-
pleted by 107 (96%) and 80 (71%) patients, respec-
tively (Supporting Fig. S1), and the mean (standard 
deviation [SD]) of duration on study was 10.6 (2.8) 
months. There were no deaths during the study, 
but one death was reported by an investigator in a 
patient after she had left the study (see On-Study 
Changes in Health Status).
DISeaSe aND tReatMeNt 
CHaRaCteRIStICS at BaSelINe
In the 12  months before study entry, patients 
reported a median (range) of 6 (0-52) attacks, with 
32% experiencing >10 attacks (Table 1). Of those 
attacks, the median number (range) that required 
hemin or treatment at a health care facility was 
4 (0-50). Patients reported a broad array of signs and 
symptoms associated with attacks (Fig. 1A). Almost 
all patients (99%) reported pain during attacks, mostly 
abdominal pain (92%), arm/leg pain (77%), and back 
pain (72%). Other common signs and symptoms 
(occurring in >80% of patients) included nausea (85%) 
and change in urine color (81%; Fig. 1A). Chronic 
symptoms occurring between attacks were reported by 
73 (65%) patients (Fig. 1B), with 52 (46%) patients 
experiencing these daily. The most common chronic 
symptoms were pain, nausea, tiredness, and anxiety.
Before entering the study, hemin treatment for 
attacks had been received by 94 (84%) patients, with 
side effects reported in 55 (59% of those who had 
received hemin) patients. Common side effects reported 
because of hemin use included headache, flu-like symp-
toms, increased iron or ferritin levels (secondary iron 
overload), phlebitis, thrombosis, and difficulties with 
venous access. Sixty-two (55%) patients reported tak-
ing medications prophylactically for AHP at baseline, 
of whom 52 (46%) patients received hemin (Table 1), 
6% were on a gonadotropin-releasing hormone analog, 
and 22% took “other” medications (including opioids, 
nonsteroidal anti-inflammatory drugs, antidepressants, 
and benzodiazepines, among others). The most com-
mon regimen reported for those on hemin prophylaxis 
was weekly (42% of patients). Rates of hemin prophy-
laxis were slightly higher in the United States (53% of 
patients) than in Europe (41% of patients). Chronic 
symptoms were reported in a similar number of AIP 
patients who received hemin prophylaxis (n  =  33 
[66%]) as those who received no hemin prophylaxis 
(n = 34 [63%]) before screening.
CoNCoMItaNt MeDICal 
HIStoRy
Medical history or conditions commonly asso-
ciated with AHP included placement of a central 
venous catheter in 45 (40%) patients, systemic arterial 
hypertension in 27 (24%) patients, and depression in 
20 (18%) patients (Supporting Table S2). In addition, 
taBle 1. patient Demographics and Disease Characteristics 
in eXploRe
Variable Patients (n = 112)
Age in years 38 (19-70)
Female sex 100 (89)
Ethnicity
White 95 (85)
Asian 3 (3)
Black 3 (3)
Not provided 11 (10)
Geographic region
Europe 63 (56)
United States 49 (44)
AHP type
AIP 104 (93)
HCP 3 (3)
VP 5 (4)
Relative with known or suspected AHP 83 (74)
Time since first attack in years 8.0 (0.5-41.1)
Number of attacks in the last 12 months 6 (0-52)
Number of attacks in the last 12 months requiring 
hemin treatment and/or hospitalization
4 (0-50)
Number of patients reporting attacks in the last 
12 months
0 attacks 6 (5)
1-2 attacks 6 (5)
3-5 attacks 42 (38)
6-10 attacks 22 (20)
>10 attacks 36 (32)
Patients experiencing chronic AHP symptoms 73 (65)
Patients who received prior hemin treatment for 
attacks
94 (84)
Current hemin prophylaxis 52 (46)
Weekly dosing 22 (42)
Monthly dosing 10 (19)
Unknown dosing 4 (8)
Other 16 (31)
Time in years on hemin prophylaxis 5 (0-26)
Note: Data are presented as n (%) or median (range).
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FIg. 1. Percentage of patients reporting attack or chronic symptoms at baseline. (A) Attack symptoms and (B) chronic symptoms. 
Symptom categories (pain, mood/sleep, GI, and other) were used when collecting data from patients to aid the reporting process. 
Chronic symptoms between attacks were reported by 73 (65%) patients; percentages are based on these 73 patients. Abbreviation: GI, 
gastrointestinal.
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12 (11%) patients experienced renal or urinary disor-
ders, including 5 (4%) patients with renal failure and an 
additional 3 (3%) patients with CKD, based on medical 
history. Three (3%) patients had a history of infection 
related to a central venous catheter and 5 (4%) patients 
had experienced thrombotic events related to a central 
catheter. All patients reported taking at least one prior 
and ongoing medication at the time of study entry. The 
most common medications were those used to treat or 
prevent AHP symptoms, including hemin in 83 (74%) 
patients, natural opium alkaloids in 62 (55%) patients, 
parenteral glucose solutions in 37 (33%) patients, and 
extra oral carbohydrates in 30 (27%) patients. The 
most frequently reported other porphyria-related med-
ications were paracetamol (25%), ondansetron (22%), 
gabapentin (13%), and lorazepam (11%).
oN-StUDy attaCK 
CHaRaCteRIStICS aND 
tReatMeNt
During the study, 98 (88%) patients experienced a 
total of 483 attacks. Of these, 371 (77%) required treat-
ment at a health care facility and/or hemin adminis-
tration, with a higher frequency in patients with AIP 
(79%) than patients with HCP and VP (44%; Table 2). 
The most common treatment location was an inpa-
tient ward (33%), followed by home (31%). Hemin 
treatment was used in 69% of attacks and opioids were 
used in 54% of attacks (Table 2). The median AAR 
for attacks requiring treatment at a health care facil-
ity and/or hemin administration was 2.0 (0.0-37.0). 
The median AAR was similar for patients with AIP 
versus patients with HCP or VP (Table 3). The AAR 
for attacks requiring treatment at a health care facility 
and/or hemin administration was similar for patients 
who completed 6  months (n  =  107) and those who 
completed the optional extension to 12  months 
(n  =  80). The AAR for attacks requiring treatment 
at a health care facility and/or hemin administration 
was also similar whether patients were in the United 
States or Europe, receiving or not receiving hemin 
prophylaxis at study entry or on study, or reporting 
or not reporting chronic daily AHP symptoms at 
study entry (Table 3). Similar trends were observed 
for all on-study attacks (including attacks treated at 
home without hemin), with a median (range) AAR 
of 3.4 (0.0-37.0) in patients with AIP, 3.3 (1.5-6.0) in 
patients with HCP and VP, and 3.4 (0.0-37.0) attacks 
in all patients (Supporting Table S3). The mean (SD) 
duration of attacks requiring treatment at a health 
care facility and/or hemin administration was 7.3 (6.0) 
days and was higher in patients with HCP and VP 
than patients with AIP (Table 3).
BaSelINe aND oN-StUDy 
BIoMaRKeR aSSeSSMeNtS
The nonattack mean (SD) urine ALA levels (all 
samples collected excluding those taken during an 
taBle 2. Characteristics of attack treatment During eXploRe
Variable AIP (n = 104) VP and HCP (n = 8) Total (n = 112)
Total attacks 458 25 483
Requiring hemin or treatment at a health care facility 360 (79) 11 (44) 371 (77)
Attacks by treatment location
Home 133 (29) 15 (60) 148 (31)
Health care facility 324 (71) 10 (40) 334 (69)
Inpatient ward 156 (34) 5 (20) 161 (33)
Infusion center 62 (14) 2 (8) 64 (13)
Clinic office 58 (13) 3 (12) 61 (13)
Emergency room 47 (10) 0 (0) 47 (10)
Unknown 1 (<1) 0 (0) 1 (<1)
Treatment type
Hemin 323 (71) 9 (36) 332 (69)
Opioids 250 (55) 12 (48) 262 (54)
Other (carbohydrates, NSAIDs, other) 202 (44) 15 (60) 217 (45)
Note: Data are presented as n (%).
Abbreviation: NSAID, nonsteroidal anti-inflammatory drug.
Hepatology, Month 2019GOUYA ET AL.
8
attack or when affected by hemin treatment) when 
they were not experiencing attacks (baseline and during 
study period) were 14.1 (9.5) mmol/mol creatinine in 
patients with AIP and 3.6 (3.4) mmol/mol creatinine in 
patients with HCP and VP (although there were only 8 
patients with HCP or VP; Supporting Fig. S2A). These 
values compare with an upper limit of normal (ULN) 
of 1.5 mmol/mol creatinine for urinary ALA in healthy 
non-AHP individuals as determined by LC-MS/MS 
assay (see Study Assessments).(35) The nonattack mean 
(SD) urine PBG levels were 32.1 (18.6) mmol/mol cre-
atinine in patients with AIP and 1.6 (2.4) mmol/mol 
creatinine in patients with HCP and VP (Supporting 
Fig. S2B). These values compare with healthy non-
AHP individuals in whom the ULN for urinary PBG 
is 0.14 mmol/mol creatinine as determined by LC-MS/
MS assay (see Study Assessments).(35)
During attacks on study (any attack type), the 
maximum urine ALA and PBG levels increased by 
an average of 193% and 146%, respectively, com-
pared with the nonattack mean (Fig. 2A and 2B). For 
attacks that required treatment at a health care facility 
or with hemin, mean peak urine ALA and PBG val-
ues were slightly higher compared with other attack 
types (220% and 164%, respectively, for all patients). 
Following treatment with hemin, mean ALA and 
PBG levels decreased to near or below levels recorded 
between attacks.
At baseline (measured in all patients, one sam-
ple per patient), normalized urine ALAS1 mRNA 
levels were approximately 4-fold above levels in 
normal healthy individuals and approximately 
2-fold above levels in chronic high-excreter patients 
(patients with AHP mutations and elevated urinary 
ALA/PBG levels but not experiencing acute attacks), 
as reported in the literature.(36) Baseline normalized 
ALAS1 mRNA levels were approximately 2-fold 
higher in patients with AIP than in patients with 
HCP and VP (Supporting Fig. S2C). During an 
attack, urine ALAS1 mRNA levels increased by 
approximately 33% above the nonattack mean 
(Fig. 2C). Following treatment with hemin, mean 
ALAS1 mRNA levels decreased to 27% below the 
nonattack mean.
oN-StUDy CHaNgeS IN HealtH 
StatUS
During the study, 96 (86%) patients experienced 
at least one change in health status, and 6% expe-
rienced at least one adverse event (change in health 
status related to study procedure, e.g., vessel punc-
ture site bruise); all were mild or moderate in sever-
ity and none led to study discontinuation. No serious 
adverse events occurred. The most common on-study 
changes in health status, as reported by investigators, 
were headache in 15 (13%) patients, nasopharyngitis 
in 14 (13%) patients, influenza and systemic arterial 
hypertension in 9 (8%) patients, gastroenteritis and 
arthralgia in 8 (7%) patients, and fatigue, pyrexia, and 
taBle 3. Characteristics of attacks Requiring treatment at a Health Care Facility and/or Hemin administration experienced 
During eXploRe
Variable AIP (n = 104) HCP and VP (n = 8) Total (n = 112)
Number of attacks 2 (0-37) 1 (0-4) 2 (0-37)
Attack duration per subject (days) 6.7 (3.4) 15.1 (18.1) 7.3 (6.0)
AAR 2.0 (0.0-37.0) 1.3 (0.0-4.2) 2.0 (0.0-37.0)
AAR by region
Europe 1.0 (0-37.0) 1.2 (1.0-1.5) 1.0 (0-37)
US 3.3 (0.0-15.9) 1.5 (0.0-4.2) 2.1 (0.0-15.9)
AAR by hemin prophylaxis*
Yes 2.5 (0.0-20.0) 3.1 (1.9-4.2) 2.5 (0.0-20.0)
No 2.0 (0.0-37.0) 1.0 (0.0-2.0) 1.5 (0.0-37.0)
AAR by daily symptoms†
Yes 2.0 (0.0-22.3) 1.0 (0.0-4.2) 2.0 (0.0-22.3)
No 2.8 (0.0-37.0) 1.9 (1.0-2.0) 2.0 (0.0-37.0)
Note: Data are presented as median (range) or mean (SD). AAR is annualized attack rate, calculated (number of attacks ÷ time on study).
*At study entry or on study.
†At study entry.
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extremity pain in 7 (6%) patients. Changes in health 
status related to central venous catheters were observed 
in 8 (7%) patients overall and included (in 1 patient 
each) thrombosis in device, infusion site thrombosis, 
embolism, superior vena cava syndrome, Clostridium 
diff icile infection, bacterial sepsis, fungal sepsis, sys-
temic inflammatory response syndrome, and septic 
shock. One patient with AIP with a history of CKD 
and chronic pancreatitis left the study at 6  months 
because of deteriorating health and subsequently died 
because of end-stage chronic liver disease judged by 
the treating physician to be secondary to AIP.
BaSelINe aND oN-StUDy 
laBoRatoRy aSSeSSMeNtS
Mean values for liver function tests, hematology, 
serum chemistry, and renal parameters remained rel-
atively constant over the course of the study. At base-
line, approximately 16% of all patients had elevations 
of liver aminotransferases (>1 × ULN and <3 × ULN). 
One patient had an increase in alanine aminotransfer-
ase and aspartate aminotransferase from ≤3 × ULN at 
study entry to between >5  ×  ULN and ≤10  ×  ULN 
at the Month 12 visit. The cause of this elevation 
was not reported. The patient did not experience an 
AHP attack at this time and had not had any changes 
in concomitant medications at or shortly before the 
time of the elevations. Seventy-six (68%) patients had 
reduced eGFR (<90  mL/min/1.73  m2) during the 
study, including 31 (28%) patients who met the crite-
ria for stage 3a, 3b, or 4 CKD,(37) based on an eGFR 
level of 15-59 mL/min/1.73 m2.(38)
BaSelINe aND oN-StUDy Qol
Overall, patients with AHP experiencing recur-
rent attacks had low QoL at baseline and throughout 
the study. At baseline, mean (SD) EQ-5D-5L Index 
Scores were 0.78 (0.15) in a patient population with 
a median age of 38  years, which is lower than the 
European population norm of 0.92 for EQ-5D-5L 
(for the 35-44 age group).(39) Self-rated health sta-
tus using a mean (SD) EQ-5D-5L visual analog scale 
was decreased to 66 (100 signifying maximal score 
and best health) at baseline and remained stable over 
the course of the study. Visual analog scale scores were 
similar whether or not a patient had ever used pro-
phylactic hemin. The three dimensions most affected 
FIg. 2. Urine ALA, PBG, and ALAS1 mRNA measurements 
during the study for all AHP types. (A) ALA, (B) PBG, and 
(C) ALAS1 mRNA. The vertical lines represent the most extreme 
point within 1.5 interquartile ranges. The bottom and top edges 
of the box indicate intraquartile range. The line inside the box 
indicates the median value. Nonattack mean is the average of 
all samples collected (excluding those taken during an attack or 
when affected by hemin treatment) for each patient. Attack peak 
is the maximum value recorded during an attack for each patient. 
Abbreviation: cr, creatinine.
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by AHP, with at least some problems noted, were 
pain and discomfort (72 [64%] patients), anxiety and 
depression (57 [51%] patients), and ability to perform 
usual activities (57 [51%] patients; Fig. 3).
BaSelINe aND oN-StUDy 
HealtH CaRe UtIlIZatIoN aND 
eCoNoMIC IMpaCt
Overall, patients with AHP reported a high level 
of health care utilization during EXPLORE. At 
12 months, patients reported a mean (SD) of 3.6 (8.6) 
emergency room visits and 5.1 (14.9) overnight hos-
pital stays while on study. Health care utilization 
was similar regardless of whether or not patients had 
ever been treated with prophylactic hemin. AHP 
also had a significant economic impact on patients. 
Sixty-eight percent of patients were not in full-time 
work at Month 12; of those who were employed part 
time or full time, 52% reported missing many days of 
work in the last 12 months because of their porphyria 
(mean [SD] 40.2 [53.9] days missed). Approximately 
one fifth (21%) of patients had received disability 
payments because of AHP in the past 12  months 
during the study, with levels similar between US and 
European patients.
Discussion
EXPLORE is a multinational, prospective, obser-
vational study designed to evaluate the disease activity 
and clinical management of severely affected patients 
with AHP who experience recurrent attacks or are 
on treatment to prevent attacks. Such information is 
central to understanding the disease manifestations, 
as well as assessing the need for and evaluation of 
the benefits and risks of potential new therapies. The 
study population had a history of recurrent attacks 
(defined in this study as ≥3 attacks per year) or were 
on prophylactic treatment to prevent attacks. There 
was a wide range in the number of attacks experienced 
by patients, with approximately one third report-
ing >10 attacks in the 12 months before enrollment. 
Consistent with the literature, symptoms commonly 
experienced during attacks included pain, nausea, 
muscle weakness, and tiredness.(12,13) Unique to this 
study was the high percentage of patients reporting a 
change in urine color, trouble sleeping, and problems 
with mental function (potentially because of effects 
on the central nervous system) during attacks.
A substantial number of patients (approximately 
two thirds) reported chronic AHP symptoms between 
attacks, with almost half reporting these symp-
toms daily. This number is considerably higher than 
reported in other observational studies (ranging from 
18% to 22%)(13,14) but likely reflects the more severely 
affected patient population in this study and that some 
of the questionnaires were completed directly by the 
patients. AAR was similar whether patients reported 
chronic daily symptoms or not, suggesting this is not 
a strong predictor of attack frequency. Chronic symp-
toms were also reported to a similar extent whether or 
not a patient was on hemin prophylaxis.
FIg. 3. Patients reporting problems affecting QoL across the five dimensions of EQ-5D-5L.
?????????????????????? ??????????????? ?????????????????? ?????? ???????? ????????????????????????????? ?????????? ???????
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All countries in the study, except Bulgaria, had 
hemin available for attack treatment, with 84% of 
the patients reporting prior hemin treatment for 
an attack. As prophylactic use of hemin is off-label, 
access can vary by region. In this patient group, treat-
ment practices observed with hemin prophylaxis were 
similar across geographic regions, although a some-
what higher rate of hemin prophylaxis was noted in 
the United States than in Europe. However, AAR was 
similar in the United States and Europe and between 
patients receiving or not receiving hemin prophy-
laxis on study or at study entry in this patient group. 
Consistent with the literature, approximately half of 
the study population were taking opioid analgesics at 
study entry during and/or between attacks, supporting 
the data indicating that the disease has chronic mani-
festations requiring further treatment.(26)
The most common comorbid conditions reported 
in the medical history at baseline were consistent with 
the known natural history of patients with AHP.(13,40) 
Although renal disorders were reported in ~10% of 
patients in the medical history, approximately 70% 
had an abnormal eGFR (<90 mL/min/1.73 m2), and 
30% met the criteria for stage 3a, 3b, or 4 CKD. CKD 
is reported to impact 30%-60% of patients with AHP 
and may be due to the toxic effects of chronic, high 
levels of ALA and PBG on the kidney and influenced 
by genetic variation in the ALA transporter peptide 
transporter 2.(13,20,40,41)
As has been observed in other studies, disease 
activity in patients with AIP was detectable through 
increased biomarker levels during and between 
attacks.(31,42) At baseline, there were marked eleva-
tions in levels of urinary ALA and PBG compared 
with the ULN in healthy individuals(35) and in ALAS1 
mRNA compared with normal levels.(36) Although 
patients with HCP or VP had near-normal ALA and 
PBG levels at baseline, in all patients, ALA, PBG, 
and ALAS1 mRNA levels increased during attacks. 
This increase suggests an important pathogenetic link 
of up-regulation of hepatic ALAS1 to disease activ-
ity, although differences in ALA, PBG, and ALAS1 
mRNA levels were not analyzed for statistical signifi-
cance. This has been inferred from preclinical studies 
in cell culture and animals, inferred from liver samples 
obtained from patients, and recently demonstrated in 
a clinical study in patients with AIP who were treated 
with an investigational RNA interference therapeutic 
givosiran targeting hepatic ALAS1 mRNA.(43-46)
An association between elevated ALA and PBG 
levels and disease activity in patients with AIP has been 
reported in the literature.(31) Similarly, therapeutics 
that lower elevated ALA and PBG levels transiently 
(hemin), in a more prolonged manner (givosiran), and 
permanently (liver transplantation) have been shown 
to reduce disease activity.(30,46,47) In EXPLORE, 
hemin treatment led ALA, PBG, and ALAS1 mRNA 
levels to decrease to near or below nonattack levels. 
ALAS1 mRNA up-regulation and increased ALAS1 
enzyme activity have been demonstrated in animal 
models of AIP and in liver tissue from patients with 
refractory AIP. However, longitudinal data on changes 
in hepatic ALAS1 mRNA or ALAS1 protein levels 
have not been previously available because of the 
requirement for repeated invasive liver biopsies.(43) By 
measuring circulating ALAS1 mRNA from exosomes 
isolated from urine (methodology used in this study), 
the study confirmed the central importance of hepatic 
ALAS1 induction in AHP pathophysiology and pro-
vided a noninvasive way to measure dynamic changes 
in hepatic ALAS1, which potentially could serve as a 
marker of disease activity and therapeutic response in 
these patients.
At study entry, patients reported diminished QoL 
while not experiencing an attack compared with pop-
ulation norms, which remained relatively stable at the 
6-month and 12-month assessments and did not dif-
fer based on prophylactic hemin usage. These data are 
consistent with other studies that used EQ-5D-5L 
to demonstrate diminished QoL in patients with 
AHP.(15,48) There was also a significant economic 
burden highlighted in patients from EXPLORE 
who exhibited increased health care utilization and 
substantial numbers of lost work days, with over 
two thirds of patients not in full-time employment 
and around one quarter receiving disability payments.
A potential limitation of the study is that attacks 
were patient reported and did not require confirma-
tion by a clinician or by increases in ALA and PBG 
levels. This method of attack ascertainment, however, 
largely reflects what occurs in clinical practice after 
patients have already been diagnosed with AHP, as 
patients may not be seen by the porphyria specialist 
for every attack, and ALA and PBG are often not 
obtained or available in real time when a patient pres-
ents with a potential porphyria attack. As it is possi-
ble that patients could experience symptoms that were 
similar to those of attacks but not due to AHP, this 
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may have led to an overestimation of attack frequency. 
However, when measured once an attack was reported, 
mean ALA and PBG levels increased from baseline, 
suggesting patient-reported attacks were likely to be 
related to AHP. In addition, the attack rate during the 
study actually decreased compared with the attack rates 
reported by both the investigators and the patients in 
the year before the study. Finally, over three quarters 
of attacks required treatment at a health care facility 
and/or hemin administration, indicating these were 
serious medical events indicative of AHP attacks.
This prospective study of patients with AHP expe-
riencing recurrent attacks highlights the high level of 
disease burden in this group and demonstrates that 
chronic symptoms are present in a majority of such 
patients between attacks, diminishing their QoL. 
Overall, data from the EXPLORE study showed that 
attacks are serious and morbid events, with >75% of 
attacks requiring urgent medical treatment in a hos-
pital or health care facility and/or treatment with 
intravenous hemin. The use of hemin prophylaxis 
was reported by nearly half of patients at study entry, 
whereas more than half received opioid analgesics. 
Approximately two thirds of patients in EXPLORE 
experienced chronic symptoms between attacks, with 
almost half reporting symptoms daily.
Elevated levels of ALA, PBG, and ALAS1 mRNA 
were observed in patients with AIP outside of attacks 
and increased further during attacks. In addition, the 
disease adversely affected multiple aspects of QoL, 
increased health care utilization, and had a substantial 
economic impact. These results underscore the need 
for novel therapies that can reduce attacks and disease 
manifestations between attacks and improve patients’ 
ability to function on a daily basis.
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